Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies.
about
Gender and ethnic differences in arterial compliance in patients with intermittent claudicationLong-term survival after initial hospital admission for peripheral arterial disease in the lower extremitiesA functional murine model of hindlimb demand ischemia.The effect of claudication pain on temporal and spatial gait measures during self-paced ambulation.Impaired vascular endothelial growth factor A and inflammation in patients with peripheral artery disease.Walking economy before and after the onset of claudication pain in patients with peripheral arterial diseaseGreater endothelial apoptosis and oxidative stress in patients with peripheral artery diseaseDietary intake of participants with peripheral artery disease and claudicationGender differences in daily ambulatory activity patterns in patients with intermittent claudicationGender and racial differences in endothelial oxidative stress and inflammation in patients with symptomatic peripheral artery disease.Oxygen uptake before and after the onset of claudication during a 6-minute walk test.Optimal exercise program length for patients with claudication.Calf muscle hemoglobin oxygen saturation in patients with peripheral artery disease who have different types of exertional leg pain.The effect of metabolic syndrome components on exercise performance in patients with intermittent claudication.Apolipoprotein profiles in subjects with and without peripheral artery disease.Influence of peripheral artery disease and statin therapy on apolipoprotein profiles.Association between gait characteristics and endothelial oxidative stress and inflammation in patients with symptomatic peripheral artery disease.Physical activity is a predictor of all-cause mortality in patients with intermittent claudication.Using risk models to improve patient selection for high-risk vascular surgery.Monitored daily ambulatory activity, inflammation, and oxidative stress in patients with claudication.Resting energy expenditure in subjects with and without intermittent claudication.Sex differences in calf muscle hemoglobin oxygen saturation in patients with intermittent claudication.V.O2 Kinetics and clinical factors among patients with peripheral artery disease.Sex-specific predictors of improved walking with step-monitored, home-based exercise in peripheral artery disease.Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study.Endothelial Cell Inflammation and Antioxidant Capacity are Associated With 6-Minute Walk Performance in Patients With Symptomatic Peripheral Artery Disease.Endothelial Cell Inflammation and Antioxidant Capacity are Associated With Exercise Performance and Microcirculation in Patients With Symptomatic Peripheral Artery Disease.Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
P2860
Q30476756-96E94A1D-567C-4506-B8D3-61E40E5E3224Q33498124-D4EE090F-7A51-4260-836D-FE7D1DCBE6EDQ33549031-EBF2814A-CD51-4F1D-AFC3-42B41981BC02Q33606174-D3595EE4-8599-4C9B-A169-FC86F6C7369FQ33707341-6C3398B7-8AAD-4EF6-A20C-A9A410E04876Q33741606-06A567A3-84DD-4B2B-A847-17A98224CC6DQ33745594-1D96DB68-66E0-43CE-AC61-939478B1C793Q34078411-01FBA5EB-620C-4709-BC78-DAFCD0049774Q34283394-0DF36B0B-2F87-4CF6-B92F-5DC9AFC7D776Q34288235-19CB1386-810E-4B0D-B57C-5681F7D0EF21Q35456920-113CD513-59EB-42AF-BDFA-0457E4B5FD5FQ35923323-F5B4FDB1-4D1C-45A8-A513-81D1391B3383Q35981596-2D54F02E-3ADE-47FE-B4E8-52AA5660D254Q36756293-0C097190-76AE-4BFB-BBD6-D1733435260CQ37120783-3FEF79B5-40DF-4351-8649-0C9DE28E657EQ37206137-3CAA9DF2-98CF-4F48-AADE-6CBE7BBDB1A5Q37219653-34EECF59-A71E-491E-A13E-B53862D0E113Q37239423-EE6C9898-D91E-473E-A964-C76748FC25C8Q37288327-8AC6F3AA-D6D1-413F-AAD8-0B416E2D2E91Q37344502-C3EF2A6A-1C73-4992-98E2-09BB7E404B29Q37380999-4652152A-05F2-4314-98B8-E7CEFA71E2B3Q37396326-4FA5C574-3F2F-455F-BE3A-AC1C3CB1AC03Q37464441-1554F089-F232-4CAC-810B-F0A4B3CC140AQ38406746-C1B8736E-772A-457C-93AD-0E5404622FFEQ39941147-6D5F9D06-EE7A-416E-BF21-1E74FDDD88E5Q40073289-C259C8A2-DD5D-43A1-935B-71383A04E978Q46784586-8557F025-168E-4920-9F85-3C4D9CF2EDD7Q51772195-FDC887D6-6161-49EC-B89A-3FA09FD17F03
P2860
Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Review of mortality and cardio ...... ls for claudication therapies.
@ast
Review of mortality and cardio ...... ls for claudication therapies.
@en
type
label
Review of mortality and cardio ...... ls for claudication therapies.
@ast
Review of mortality and cardio ...... ls for claudication therapies.
@en
prefLabel
Review of mortality and cardio ...... ls for claudication therapies.
@ast
Review of mortality and cardio ...... ls for claudication therapies.
@en
P2860
P356
P1433
P1476
Review of mortality and cardio ...... ls for claudication therapies.
@en
P2093
Eric P Brass
William R Hiatt
P2860
P304
P356
10.1177/1358863X06069513
P577
2006-11-01T00:00:00Z